Virginia Commonwealth University Health System, Richmond, Virginia, USA.
Columbia University Irving Medical Center, New York, New York, USA.
Curr Opin Hematol. 2018 Nov;25(6):482-485. doi: 10.1097/MOH.0000000000000457.
We review recent articles pertaining to the use of tranexamic acid (TXA) in populations at risk for massive transfusion. Although there are no recent studies that specifically examine the use of TXA in massive transfusion protocols (MTPs), there are a few studies with subgroups of massive transfusion patients.
In recent years, many publications have discussed outcomes and safety associated with the addition of TXA to treatment plans for bleeding pediatric, trauma, and postpartum hemorrhage patients. In general, TXA appears to decrease mortality and transfusion requirements.
TXA was shown to decrease mortality in several bleeding populations. It is now a common addition to MTPs. There is conflicting evidence regarding the potential of TXA as a risk factor for thrombotic events. Ongoing studies should provide additional evidence regarding the thrombotic risk of TXA in massive transfusion.
我们回顾了最近与大出血风险人群中使用氨甲环酸（TXA）相关的文章。尽管最近没有专门研究 TXA 在大出血治疗方案（MTP）中应用的研究，但有一些研究包含了大出血患者的亚组。
近年来，许多出版物讨论了 TXA 加入儿科、创伤和产后出血患者出血治疗方案相关的结果和安全性。一般来说，TXA 似乎可以降低死亡率和输血需求。
TXA 已被证明可降低几种出血人群的死亡率。它现在是 MTP 的常见添加物。关于 TXA 是否可能成为血栓事件的危险因素，证据存在冲突。正在进行的研究应该提供关于 TXA 在大出血中血栓形成风险的更多证据。
